Atai Life Sciences EBITDA 2020-2025 | ATAI
Atai Life Sciences ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Atai Life Sciences Annual EBITDA (Millions of US $) |
2024 |
$-102 |
2023 |
$-125 |
2022 |
$-145 |
2021 |
$-136 |
2020 |
$-104 |
2019 |
$-18 |
Atai Life Sciences Quarterly EBITDA (Millions of US $) |
2025-03-31 |
$-20 |
2024-12-31 |
$-30 |
2024-09-30 |
$-23 |
2024-06-30 |
$-26 |
2024-03-31 |
$-24 |
2023-12-31 |
$-33 |
2023-09-30 |
$-27 |
2023-06-30 |
$-32 |
2023-03-31 |
$-33 |
2022-12-31 |
$-38 |
2022-09-30 |
$-38 |
2022-06-30 |
$-35 |
2022-03-31 |
$-33 |
2021-12-31 |
$-45 |
2021-09-30 |
$-33 |
2021-06-30 |
$-61 |
2021-03-31 |
$4 |
2020-12-31 |
$-87 |
2020-09-30 |
$-7 |
2020-06-30 |
$-6 |
2020-03-31 |
$-4 |
2019-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Outpatient & Home Care |
$0.541B |
$0.000B |
atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
|